Malarone Enfants

Atovaquone/Proguanil, the active ingredient in Malarone Enfants, is an antimalarial presented as a dispersible tablet for oral use. It is indicated for the prevention of malaria infection and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in pediatric patients, and it complies with European Union marketing standards.

GNH USA supplies Malarone Enfants as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, providing reliable sourcing for malaria prophylaxis and treatment programs and supporting public health initiatives.

Malarone Enfants (atovaquone/proguanil) is used in the antiprotozoal class to prevent and treat malaria infections.

Prevention of malaria: provides chemoprophylaxis for children traveling to or residing in endemic areas. Acute uncomplicated malaria (P. falciparum): treats infection in pediatric patients with rapid parasite clearance. Chloroquine‑resistant malaria: offers an effective alternative for strains resistant to chloroquine in children.

Malarone Enfants may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Abdominal pain: intermittent stomach cramps. - Vomiting: occasional expulsion of stomach contents. - Loss of appetite: reduced desire to eat. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: signs of liver dysfunction including jaundice. - Hemolysis in G6PD deficiency: rapid breakdown of red blood cells. - Anaphylaxis: acute allergic response requiring emergency care. - Blood dyscrasias: abnormal blood cell counts. - Severe allergic reactions: including rash, swelling, and breathing difficulty.

Before prescribing Malarone Enfants, clinicians should evaluate patient history and monitor for specific risks.

Assess medical history: confirm no known hypersensitivity to atovaquone or proguanil. Evaluate liver function: use with caution in patients with hepatic impairment. Consider renal function: adjust if severe renal disease is present. Avoid use in patients with known G6PD deficiency without specialist advice. Pregnancy and breastfeeding: discuss potential risks with a healthcare professional. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone Enfants can interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations. - Protease inhibitors (e.g., ritonavir): may increase atovaquone exposure and risk of toxicity. - Cimetidine: can raise proguanil levels, increasing side‑effect potential.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect, requiring INR monitoring. - Phenytoin: may lower atovaquone concentrations, reducing efficacy. - Macrolide antibiotics (e.g., erythromycin): can increase proguanil levels, necessitating clinical observation.